Frederic Marin

Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.

At gmp-orphan (GMPO), it is our mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Our experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission. gmp-orphan (GMPO) was founded in 2011 and the company’s most advanced product candidate is Cuprior for the treatment of Wilson Disease.

Polepharma structure la filière industrielle (bio)pharmaceutique française et accompagne sa transformation depuis 20 ans. Polepharma est devenue la 1ère coopération industrielle du médicament en Europe, entre des terres d’excellence et les acteurs de la filière : 400+ membres, 60% de la production & 70k emplois en France. Implanté dans 5 territoires (Centre-Val de Loire, Ile-de-France, Normandie, Occitanie, Nouvelle-Aquitaine), Polepharma anime ses adhérents partout en France. Ce sont des laboratoires, fournisseurs, écoles, collectifs, experts, talents qui veulent faire de la France le meilleur endroit au monde où développer & produire des médicaments, c’est-à-dire à la pointe, vertueux, attractif pour le business et les talents. Fabriquer des traitements de qualité en France, préventifs & curatifs, dans les meilleures conditions, sécurise notre santé à tous, contribue à l’emploi et aux économies locales. La France s’est fixé pour priorité d’assurer sa souveraineté sanitaire. Pour y arriver, elle doit regagner son leadership européen et accélérer la transition de son industrie (bio)pharmaceutique. Seule une action collective, permettra de relever ces défis. AUDACE, FIERTÉ ET COOPÉRATION

OUR MISSION: Protecting Lives Against Radiation Threats. USIL Therapeutics pioneers breakthrough medical solutions to safeguard people from the dangers of ionizing radiation. Our mission is to transform radiation defense with treatments and potential cures that go beyond symptomatic care, delivering true whole-body protection. Partnering with governments, defense, and energy sectors worldwide, we provide scalable, effective countermeasures that strengthen resilience and global preparedness in the face of nuclear and radiological risks.

At gmp-orphan (GMPO), it is our mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Our experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission. gmp-orphan (GMPO) was founded in 2011 and the company’s most advanced product candidate is Cuprior for the treatment of Wilson Disease.

OP2 Drugs SAS ("OP2"​) is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational. Based on strategic partnerships in Europe and in the US, we are generatling growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 Drugs is planned to move forward to clinic in 2018. Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Michel Andraud (CFO), and funded by ambitious financial players.

Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.

At gmp-orphan (GMPO), it is our mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Our experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission. gmp-orphan (GMPO) was founded in 2011 and the company’s most advanced product candidate is Cuprior for the treatment of Wilson Disease.